Evidence map›Paper›PMID 40841695›Full record

ArticleActa neuropathologica communications2025

Correction: Biglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling.

Konstantin Okonechnikov, David R Ghasemi, Daniel Schrimpf, Svenja Tonn, Martin Mynarek, Jan Koster, Till Milde, Tuyu Zheng, Philipp Sievers, Felix Sahm and 6 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Konstantin OkonechnikovHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
David R GhasemiHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Daniel SchrimpfHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Svenja TonnPediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Martin MynarekPediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jan KosterCenter for Experimental and Molecular Medicine, Amsterdam University Medical Centers, University of Amsterdam and Cancer Center Amsterdam, Amsterdam, The Netherlands.
Till MildeHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Tuyu ZhengHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Philipp SieversClinical Cooperation Unit Neuropathology (B300), German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Felix SahmHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
David T W JonesHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Andreas von DeimlingHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Stefan M PfisterHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Marcel KoolHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Kristian W PajtlerHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Andrey KorshunovHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. andrey.korshunov@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40841695
PMCPMC12372277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.